230 related articles for article (PubMed ID: 18446218)
1. Reactivation of human herpesvirus-6 in natalizumab treated multiple sclerosis patients.
Yao K; Gagnon S; Akhyani N; Williams E; Fotheringham J; Frohman E; Stuve O; Monson N; Racke MK; Jacobson S
PLoS One; 2008 Apr; 3(4):e2028. PubMed ID: 18446218
[TBL] [Abstract][Full Text] [Related]
2. Asymptomatic reactivation of JC virus in patients treated with natalizumab.
Chen Y; Bord E; Tompkins T; Miller J; Tan CS; Kinkel RP; Stein MC; Viscidi RP; Ngo LH; Koralnik IJ
N Engl J Med; 2009 Sep; 361(11):1067-74. PubMed ID: 19741227
[TBL] [Abstract][Full Text] [Related]
3. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
4. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
[TBL] [Abstract][Full Text] [Related]
5. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
[TBL] [Abstract][Full Text] [Related]
6. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.
Iannetta M; Zingaropoli MA; Bellizzi A; Morreale M; Pontecorvo S; D'Abramo A; Oliva A; Anzivino E; Lo Menzo S; D'Agostino C; Mastroianni CM; Millefiorini E; Pietropaolo V; Francia A; Vullo V; Ciardi MR
PLoS One; 2016; 11(8):e0160277. PubMed ID: 27486658
[TBL] [Abstract][Full Text] [Related]
9. Immunological hallmarks of JC virus replication in multiple sclerosis patients on long-term natalizumab therapy.
Hendel-Chavez H; de Goër de Herve MG; Giannesini C; Mazet AA; Papeix C; Louapre C; Chardain A; Boutarfa N; Théaudin M; Adams D; Gasnault J; Stankoff B; Taoufik Y
J Virol; 2013 May; 87(10):6055-9. PubMed ID: 23514886
[TBL] [Abstract][Full Text] [Related]
10. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
11. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
[TBL] [Abstract][Full Text] [Related]
12. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
[TBL] [Abstract][Full Text] [Related]
13. Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Kohlmann R; Salmen A; Chan A; Knabbe C; Diekmann J; Brockmeyer N; Skaletz-Rorowski A; Michalik C; Gold R; Überla K
Mult Scler; 2015 Dec; 21(14):1823-32. PubMed ID: 25828755
[TBL] [Abstract][Full Text] [Related]
14. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
[TBL] [Abstract][Full Text] [Related]
15. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
16. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
17. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
[TBL] [Abstract][Full Text] [Related]
18. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
19. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
20. JCPyV miR-J1-5p in Urine of Natalizumab-Treated Multiple Sclerosis Patients.
Agostini S; Mancuso R; Costa AS; Caputo D; Clerici M
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]